Background: We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. Methods: In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher's exact test, chi square test, or McNemar's test, as appropriate, to evaluate between-group differences. Results: We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) (p < 0.001), and similar to the low-risk population (n = 11, 1.3%) (p = 0.057); these results were also confirmed after random matching by age and sex (1:1:1). No significant differences were found in demographic, clinical, treatment, and laboratory features. Among MS patients positive to SARS-CoV-2 IgG/IgM (n = 9), only two patients retrospectively reported mild and short-lasting COVID-19 symptoms. Conclusions: MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression.

Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg / Capasso, Nicola; Palladino, Raffaele; Montella, Emma; Pennino, Francesca; Lanzillo, Roberta; Carotenuto, Antonio; Petracca, Maria; Iodice, Rosa; Iovino, Aniello; Aruta, Francesco; Pastore, Viviana; Buonomo, Antonio Riccardo; Zappulo, Emanuela; Gentile, Ivan; Triassi, Maria; Brescia Morra, Vincenzo; Moccia, Marcello. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:12(2020), p. 4066. [10.3390/jcm9124066]

Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg

Palladino, Raffaele;Montella, Emma;Pennino, Francesca;Lanzillo, Roberta;Carotenuto, Antonio;Petracca, Maria;Iodice, Rosa;Iovino, Aniello;Aruta, Francesco;Pastore, Viviana;Buonomo, Antonio Riccardo;Zappulo, Emanuela;Gentile, Ivan;Triassi, Maria;Brescia Morra, Vincenzo;Moccia, Marcello
2020

Abstract

Background: We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. Methods: In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher's exact test, chi square test, or McNemar's test, as appropriate, to evaluate between-group differences. Results: We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) (p < 0.001), and similar to the low-risk population (n = 11, 1.3%) (p = 0.057); these results were also confirmed after random matching by age and sex (1:1:1). No significant differences were found in demographic, clinical, treatment, and laboratory features. Among MS patients positive to SARS-CoV-2 IgG/IgM (n = 9), only two patients retrospectively reported mild and short-lasting COVID-19 symptoms. Conclusions: MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression.
2020
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg / Capasso, Nicola; Palladino, Raffaele; Montella, Emma; Pennino, Francesca; Lanzillo, Roberta; Carotenuto, Antonio; Petracca, Maria; Iodice, Rosa; Iovino, Aniello; Aruta, Francesco; Pastore, Viviana; Buonomo, Antonio Riccardo; Zappulo, Emanuela; Gentile, Ivan; Triassi, Maria; Brescia Morra, Vincenzo; Moccia, Marcello. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:12(2020), p. 4066. [10.3390/jcm9124066]
File in questo prodotto:
File Dimensione Formato  
jcm-09-04066.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 261.52 kB
Formato Adobe PDF
261.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/829700
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 21
social impact